[2]
Sleeman A, Clements JN. Abaloparatide: A new pharmacological option for osteoporosis. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2019 Jan 25:76(3):130-135. doi: 10.1093/ajhp/zxy022. Epub
[PubMed PMID: 30689744]
[3]
Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2019 May 1:104(5):1595-1622. doi: 10.1210/jc.2019-00221. Epub
[PubMed PMID: 30907953]
Level 1 (high-level) evidence
[4]
Cheng C, Wentworth K, Shoback DM. New Frontiers in Osteoporosis Therapy. Annual review of medicine. 2020 Jan 27:71():277-288. doi: 10.1146/annurev-med-052218-020620. Epub 2019 Sep 11
[PubMed PMID: 31509477]
[5]
Reginster JY, Hattersley G, Williams GC, Hu MY, Fitzpatrick LA, Lewiecki EM. Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide. Calcified tissue international. 2018 Nov:103(5):540-545. doi: 10.1007/s00223-018-0450-0. Epub 2018 Jun 27
[PubMed PMID: 29951742]
[6]
Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. The Journal of clinical endocrinology and metabolism. 2020 Mar 1:105(3):. pii: dgaa048. doi: 10.1210/clinem/dgaa048. Epub
[PubMed PMID: 32068863]
[7]
Li N, Cornelissen D, Silverman S, Pinto D, Si L, Kremer I, Bours S, de Bot R, Boonen A, Evers S, van den Bergh J, Reginster JY, Hiligsmann M. An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis. PharmacoEconomics. 2021 Feb:39(2):181-209. doi: 10.1007/s40273-020-00965-9. Epub 2020 Oct 7
[PubMed PMID: 33026634]
Level 1 (high-level) evidence
[8]
Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE EXECUTIVE SUMMARY. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2020 May:26(5):564-570. doi: 10.4158/GL-2020-0524. Epub
[PubMed PMID: 32427525]
Level 1 (high-level) evidence
[9]
Kostenuik PJ, Binkley N, Anderson PA. Advances in Osteoporosis Therapy: Focus on Osteoanabolic Agents, Secondary Fracture Prevention, and Perioperative Bone Health. Current osteoporosis reports. 2023 Aug:21(4):386-400. doi: 10.1007/s11914-023-00793-8. Epub 2023 Jun 8
[PubMed PMID: 37289382]
Level 3 (low-level) evidence
[10]
Czerwinski E, Cardona J, Plebanski R, Recknor C, Vokes T, Saag KG, Binkley N, Lewiecki EM, Adachi J, Knychas D, Kendler D, Orwoll E, Chen Y, Pearman L, Li YH, Mitlak B. The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2022 Dec:37(12):2435-2442. doi: 10.1002/jbmr.4719. Epub 2022 Oct 18
[PubMed PMID: 36190391]
Level 1 (high-level) evidence
[11]
Wang MW, Yang Z, Chen X, Zhou SH, Huang GL, Sun JN, Jiang H, Xu WM, Lin HC, Yu X, Sun JP. Activation of PTH1R alleviates epididymitis and orchitis through Gq and β-arrestin-1 pathways. Proceedings of the National Academy of Sciences of the United States of America. 2021 Nov 9:118(45):. doi: 10.1073/pnas.2107363118. Epub
[PubMed PMID: 34740971]
[12]
Brent MB. Abaloparatide: A review of preclinical and clinical studies. European journal of pharmacology. 2021 Oct 15:909():174409. doi: 10.1016/j.ejphar.2021.174409. Epub 2021 Aug 5
[PubMed PMID: 34364879]
[13]
Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, Caplan L, Gore S, Grossman J, Hansen KE, Lane NE, Ma NS, Magrey M, McAlindon T, Robinson AB, Saha S, Womack C, Abdulhadi B, Charles JF, Cheah JTL, Chou S, Goyal I, Haseltine K, Jackson L, Mirza R, Moledina I, Punni E, Rinden T, Turgunbaev M, Wysham K, Turner AS, Uhl S. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis care & research. 2023 Dec:75(12):2405-2419. doi: 10.1002/acr.25240. Epub 2023 Oct 26
[PubMed PMID: 37884467]
[14]
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016 Aug 16:316(7):722-33. doi: 10.1001/jama.2016.11136. Epub
[PubMed PMID: 27533157]
Level 1 (high-level) evidence
[15]
Merlotti D, Falchetti A, Chiodini I, Gennari L. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert opinion on pharmacotherapy. 2019 May:20(7):805-811. doi: 10.1080/14656566.2019.1583208. Epub 2019 Mar 11
[PubMed PMID: 30856013]
Level 3 (low-level) evidence
[16]
Dempster DW, Zhou H, Rao SD, Recknor C, Miller PD, Leder BZ, Annett M, Ominsky MS, Mitlak BH. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2021 Apr:36(4):644-653. doi: 10.1002/jbmr.4243. Epub 2021 Jan 28
[PubMed PMID: 33434314]
[17]
Brent MB, Thomsen JS, Brüel A. The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar. Frontiers in endocrinology. 2020:11():588773. doi: 10.3389/fendo.2020.588773. Epub 2020 Oct 9
[PubMed PMID: 33162940]
[18]
Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ. Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology. 2016 Jan:157(1):141-9. doi: 10.1210/en.2015-1726. Epub 2015 Nov 12
[PubMed PMID: 26562265]
[19]
Matsumoto T, Sone T, Soen S, Tanaka S, Yamashita A, Inoue T. Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study. The Journal of clinical endocrinology and metabolism. 2022 Sep 28:107(10):e4222-e4231. doi: 10.1210/clinem/dgac486. Epub
[PubMed PMID: 35977548]
[20]
Miller PD, Troy S, Weiss RJ, Annett M, Schense J, Williams SA, Mitlak B. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density. Clinical drug investigation. 2021 Mar:41(3):277-285. doi: 10.1007/s40261-021-01008-7. Epub 2021 Feb 27
[PubMed PMID: 33638863]
[21]
Shirley M. Abaloparatide: First Global Approval. Drugs. 2017 Aug:77(12):1363-1368. doi: 10.1007/s40265-017-0780-7. Epub
[PubMed PMID: 28624872]
[22]
Hussar DA. New Drugs 2018, part 3. Nursing. 2018 Oct:48(10):32-43. doi: 10.1097/01.NURSE.0000545013.60672.65. Epub
[PubMed PMID: 30192268]
[23]
Tella SH, Kommalapati A, Correa R. Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. Cureus. 2017 May 31:9(5):e1300. doi: 10.7759/cureus.1300. Epub 2017 May 31
[PubMed PMID: 28680788]
[24]
Bilezikian JP, Hattersley G, Mitlak BH, Hu MY, Fitzpatrick LA, Dabrowski C, Miller PD, Papapoulos SE. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current medical research and opinion. 2019 Dec:35(12):2097-2102. doi: 10.1080/03007995.2019.1656955. Epub 2019 Sep 11
[PubMed PMID: 31418585]
Level 3 (low-level) evidence
[25]
Fontalis A, Kenanidis E, Kotronias RA, Papachristou A, Anagnostis P, Potoupnis M, Tsiridis E. Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss. Expert opinion on pharmacotherapy. 2019 Jun:20(9):1123-1134. doi: 10.1080/14656566.2019.1594772. Epub 2019 Apr 8
[PubMed PMID: 30958709]
Level 3 (low-level) evidence
[26]
Jolette J, Attalla B, Varela A, Long GG, Mellal N, Trimm S, Smith SY, Ominsky MS, Hattersley G. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34). Regulatory toxicology and pharmacology : RTP. 2017 Jun:86():356-365. doi: 10.1016/j.yrtph.2017.04.001. Epub 2017 Apr 4
[PubMed PMID: 28389324]
[27]
Schneider GK, Ing SW. Radiotherapy-Associated Pelvic Insufficiency Fracture Treated by Romosozumab: Course of CT Attenuations at L1 and L5. Journal of the Endocrine Society. 2022 Oct 26:6(12):bvac152. doi: 10.1210/jendso/bvac152. Epub 2022 Oct 10
[PubMed PMID: 36330291]
[28]
Lewiecki EM, Czerwinski E, Recknor C, Strzelecka A, Valenzuela G, Lawrence M, Silverman S, Cardona J, Nattrass SM, Binkley N, Annett M, Pearman L, Mitlak B. Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2023 Oct:38(10):1404-1414. doi: 10.1002/jbmr.4877. Epub 2023 Jul 27
[PubMed PMID: 37417725]
Level 1 (high-level) evidence
[29]
Haas AV, LeBoff MS. Osteoanabolic Agents for Osteoporosis. Journal of the Endocrine Society. 2018 Aug 1:2(8):922-932. doi: 10.1210/js.2018-00118. Epub 2018 Jul 9
[PubMed PMID: 30087947]
[30]
Imel EA, Starzyk K, Gliklich R, Weiss RJ, Wang Y, Williams SA. Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2020 Dec:31(12):2413-2424. doi: 10.1007/s00198-020-05388-y. Epub 2020 Jul 21
[PubMed PMID: 32696118]
[31]
Brent MB. Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies. Pharmacology & therapeutics. 2023 Apr:244():108383. doi: 10.1016/j.pharmthera.2023.108383. Epub 2023 Mar 16
[PubMed PMID: 36933702]
Level 3 (low-level) evidence